Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France

• Hauptverfasser: Matthieu Lehmann (Verfasst von), Elisangela Arbo (Verfasst von), Jean-Luc Pouly (Verfasst von), Paul Barrière (Verfasst von), Lauren Amy Boland (Verfasst von), Samuel George Bean (Verfasst von), Julian Jenkins (Verfasst von)
• Format: Buch
• Veröffentlicht: Elsevier, 2024-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Objective: The study assessed cost-effectiveness of follitropin alfa biosimilar versus the originator in terms of cost per cumulative live-birth (CLB) for the French healthcare system based on real-world evidence. Follitropin alfa biosimilars have been shown to have comparable clinical outcomes to t...